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ABSTRACT
In bone, sclerostin is mainly osteocyte‐derived and plays an important local role in adaptive responses to mechanical loading. Whether
circulating levels of sclerostin also play a functional role is currently unclear, which we aimed to examine by two‐sample Mendelian
randomization (MR). A genetic instrument for circulating sclerostin, derived from a genomewide association study (GWAS) meta‐analysis of
serum sclerostin in 10,584 European‐descent individuals, was examined in relation to femoral neck bone mineral density (BMD; n= 32,744)
in GEFOS and estimated bone mineral density (eBMD) by heel ultrasound (n= 426,824) and fracture risk (n= 426,795) in UK Biobank.
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Our GWAS identiﬁed two novel serum sclerostin loci, B4GALNT3 (standard deviation [SD]) change in sclerostin per A allele
(β= 0.20, p= 4.6× 10−49) and GALNT1 (β = 0.11 per G allele, p= 4.4 × 10−11). B4GALNT3 is an N‐acetyl‐galactosaminyltransferase,
adding a terminal LacdiNAc disaccharide to target glycocoproteins, found to be predominantly expressed in kidney, whereas
GALNT1 is an enzyme causing mucin‐type O‐linked glycosylation. Using these two single‐nucleotide polymorphisms (SNPs) as
genetic instruments, MR revealed an inverse causal relationship between serum sclerostin and femoral neck BMD (β= –0.12, 95%
conﬁdence interval [CI] –0.20 to –0.05) and eBMD (β= –0.12, 95% CI –0.14 to –0.10), and a positive relationship with fracture risk
(β= 0.11, 95% CI 0.01 to 0.21). Colocalization analysis demonstrated common genetic signals within the B4GALNT3 locus for
higher sclerostin, lower eBMD, and greater B4GALNT3 expression in arterial tissue (probability >99%). Our ﬁndings suggest that
higher sclerostin levels are causally related to lower BMD and greater fracture risk. Hence, strategies for reducing circulating
sclerostin, for example by targeting glycosylation enzymes as suggested by our GWAS results, may prove valuable in treating
osteoporosis. © 2019 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc.
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Introduction
Sclerostin is a glycoprotein produced by osteocytes, which isthought to play an important role in bone’s adaptive
response to mechanical loading, acting within the local bone
microenvironment to suppress bone formation.(1) The scler-
ostin antibody romosozumab has recently been found to
increase bone mineral density (BMD) and reduce fracture
risk,(2,3) establishing sclerostin as an important drug target for
osteoporosis. However, concerns of possible oﬀ‐target eﬀects
were raised by the ﬁnding of an increased risk of cardiovascular
events reported in a recent phase 3 trial of patients randomized
to romosozumab or alendronate.(3) Sclerostin is also detectable
in the systemic circulation, the functional role of which remains
unclear. Serum sclerostin exchanges with the bone microenvir-
onment and may simply mirror the prevalent conditions within
bone. Consistent with this suggestion, serum sclerostin has
been found to respond to physiological stimuli such as
estrogen in parallel to alterations in local bone expression.(4)
Several studies suggest that serum sclerostin exerts other roles
outside the skeleton. For example, serum sclerostin has been
reported to increase in chronic kidney disease (CKD) and may
contribute to the pathogenesis of chronic kidney disease–mineral
and bone disorder (CKD‐MBD).(5) Serum sclerostin levels are also
higher in patients with cardiovascular disease and may predict
cardiovascular mortality.(6) A relationship with glucose metabolism
has been suggested in light by reports of higher sclerostin levels
in association with type 1 and type 2 diabetes mellitus in
adolescents(7) and adults,(8) respectively. Although these changes
may represent “oﬀ‐target” eﬀects of sclerostin originating from
bone, alternatively, sclerostin might act as an endocrine hormone,
subject to regulation by as yet unidentiﬁed additional factors.
Adding to this complexity, several extraskeletal tissues have been
found to express sclerostin, including the liver, chondrocytes,
kidney, and vascular smooth muscle cells.(9) Aside from extra-
skeletal target tissues, perturbations in serum sclerostin could
conceivably aﬀect the bone itself through consequent alterations
of sclerostin levels within the local bone environment.
To the extent that circulating sclerostin levels inﬂuence bone
metabolism, this may oﬀer additional strategies for targeting
sclerostin and provide a distinct toxicity proﬁle compared with
systemic sclerostin antibody administration producing complete
abrogation of sclerostin function throughout the organism. In
the present study, we aimed to establish whether circulating
sclerostin exerts a causal inﬂuence on bone metabolism, using a
two‐sample Mendelian randomization (MR) framework.(10) With
this approach, genotypic markers for the exposure of interest are
ﬁrst identiﬁed from a genomewide association study (GWAS), to
provide an instrumental variable. Subsequently, the output of a
GWAS for the outcome, obtained in a separate population, is
interrogated for association with the instrumental variable for
the exposure. This enables causal inferences to be drawn
between exposures and outcomes based on evaluation of their
genetic determinants, despite these being measured in separate
populations. The recently published two‐sample MR, demon-
strating a null association between vitamin D and fracture risk,
represents a successful application of this approach.(11) There-
fore, we aimed to derive an instrumental variable for sclerostin
from a sclerostin GWAS and to subsequently apply this to
outputs from previously published large‐scale bone mineral
density (BMD) and fracture GWASs.
Materials and Methods
Cohort details
The Avon Longitudinal Study of Parents and Children (ALSPAC)
ALSPAC is a prospective birth cohort that recruited pregnant
women with expected delivery dates between April 1991 and
December 1992 from Bristol, UK. The initial number of
pregnancies enrolled was 14,541 (for these at least one
questionnaire has been returned or a “Children in Focus” clinic
had been attended by July 19, 1999). Of these initial
pregnancies, there was a total of 14,676 fetuses, resulting in
14,062 live births and 13,988 children who were alive at 1 year
of age. Detailed information on health and development of
children and their parents were collected from regular clinic
visits and completion of questionnaires.(12,13) Ethical approval
was obtained from the ALSPAC Law and Ethics Committee and
the Local Ethics Committees. Please note that the study
website contains details of all the data that is available through
a fully searchable data dictionary (http://www.bristol.ac.uk/
alspac/researchers/our‐data/).
Die Deutsche Diabetes Dialyse Studie (4D)
The 4D study was a prospective randomized controlled trial
including patients with type 2 diabetes mellitus who had been
treated by hemodialysis for less than 2 years.(14) Between March
1998 and October 2002, 1255 patients were recruited in 178
dialysis centers in Germany. Patients were randomly assigned
to double‐blinded treatment with either 20mg of atorvastatin
(n= 619) or placebo (n= 636) once daily and were followed up
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until the date of death, censoring, or end of the study in March
2004. The primary endpoint of the 4D study was deﬁned as a
composite of death due to cardiac causes, stroke, and
myocardial infarction, whichever occurred ﬁrst. 4D study
endpoints were centrally adjudicated by 3 members of the
endpoints committee blinded to study treatment and ac-
cording to predeﬁned criteria. The study was approved by the
medical ethics committees, and written informed consent was
obtained from all participants.
The Gothenburg Osteoporosis and Obesity Determinants (GOOD)
The GOOD study was initiated to determine both environ-
mental and genetic factors involved in the regulation of bone
and fat mass.(15) Male study subjects were randomly identiﬁed
in the greater Gothenburg area in Sweden using national
population registers, contacted by telephone, and invited to
participate. To be enrolled in the GOOD study, subjects had to
be between 18 and 20 years of age. There were no other
exclusion criteria, and 49% of the study candidates agreed to
participate (n= 1068). The study was approved by the ethics
committee at the University of Gothenburg. Written and oral
informed consent was obtained from all study participants.
MANOLIS cohort
HELIC‐MANOLIS (Minoan isolates) collection comprises indivi-
duals from the mountainous Mylopotamos villages, including
Anogia, Zoniana, Livadia, and Gonies (estimated population
size of 6000 in total) on the Greek island of Crete. It is one of
the two cohorts composing the Hellenic Isolated Cohorts study
(HELIC; http://www.helic.org). The speciﬁc population ge-
netics(16) and dietary and lifestyle habits(17) of this cohort
have been previously studied in the literature. The HELIC
collections include blood for DNA extraction, laboratory‐based
hematological and biochemical measurements, and interview‐
based questionnaire data. The study was approved by the
Harokopio University Bioethics Committee, and informed
consent was obtained from human subjects.
GWAS meta‐analysis of sclerostin
Sclerostin measures in the four cohorts were standardized to
SD units. Each cohort ran a GWAS across all imputed or
sequenced variants. Age and sex were included as covariates in
all models, as were the ﬁrst 10 principal components (PCs) to
adjust for genetic stratiﬁcation. Linear mixed models BOLT‐
LMM and GEMMA were applied to ALSPAC and MONOLIS
cohort, respectively, to adjust for cryptic population structure
and relatedness. The ALSPAC, 4D, and GOOD cohorts were
imputed using Haplotype Reference Consortium (HRC) V1.0
reference panel (MANOLIS employed whole‐genome sequen-
cing). We standardized the genomic coordinates to be reported
on the NCBI build 37 (hg19) and alleles on the forward strand.
Summary‐level quality control was conducted for Europeans
only in EasyQC.(18) Meta‐analysis (using a ﬁxed‐eﬀects model
implemented in EasyQC) was restricted to variants common to
all four studies (n= 5,245,208 variants), MAF >1%, and high
imputation quality score (Rsq >0.8 for variants imputed in
MaCH(19) and info >0.8 for variants imputed in IMPUTE.(20) A
p value< 5× 10−8 in the meta‐analysis was used to deﬁne
genomewide signiﬁcant associations. Each locus is represented
in the corresponding results table by the variant with the
strongest evidence for association. A random‐eﬀects model
meta‐analysis was also conducted using GWAMA version
2.2.2.(21) Heterogeneity was assessed using the I2 statistic and
Cochrane’s Q test.
Conditional analysis and genetic ﬁne mapping
To detect multiple independent association signals at each of
the genomewide signiﬁcant sclerostin loci, we carried out
an approximate conditional and joint genomewide association
analysis using the software package GCTA‐COJO.(22) Single‐
nucleotide polymorphisms (SNPs) with high collinearity
(correlation r2 > 0.9) were ignored, and those situated more
than 10 Mb away were assumed to be in complete linkage
equilibrium. A reference sample of 8890 unrelated individuals
of ALSPAC mothers was used to model patterns of linkage
disequilibrium (LD) between variants. The reference geno-
typing data set consisted of the same 5 million variants
assessed in our GWAS. Conditionally independent variants that
reached GWAS signiﬁcance were annotated to the physically
closest gene with the Hg19 Gene range list available in dbSNP
(https://www.ncbi.nlm.nih.gov/SNP/).
Estimation of SNP heritability using LD‐score regression
To estimate the amount of genomic inﬂation in the data due to
residual population stratiﬁcation, cryptic relatedness, and other
latent sources of bias, we used LD score regression.(23) LD
scores were calculated for all high‐quality SNPs (ie, INFO
score >0.9 and MAF >0.1%) from the meta‐analysis. We further
quantiﬁed the overall SNP‐based heritability’s with LD score
regression using a subset of 1.2 million HapMap SNPs.
Estimation of genetic correlations using LD Hub
To estimate the genetic correlation between sclerostin and
bone phenotypes related to osteoporosis, we used a recent
method based on LD score regression as implemented in the
online web utility LD Hub.(24) This method uses the cross‐
products of summary test statistics from two GWASs and
regresses them against a measure of how much variation each
SNP tags (its LD score). Variants with high LD scores are more
likely to contain more true signals and thus provide a greater
chance of overlap with genuine signals between GWASs. The
LD score regression method uses summary statistics from the
GWAS meta‐analysis of sclerostin and the bone phenotypes,
calculates the cross‐product of test statistics at each SNP, and
then regresses the cross‐product on the LD score.
Genetic colocalization analysis between sclerostin and bone
phenotypes
We used a stringent Bayesian model (coloc) to estimate the
posterior probability (PP) of each genomic locus containing a
single variant aﬀecting both serum sclerostin level and bone
phenotypes.(25) A lack of evidence (ie, PP< 80%) in this analysis
would suggest that one of the causal variants for protein is
simply in LD with the putative causal variant for the trait (thus
introducing genomic confounding into the association be-
tween sclerostin level and bone phenotypes). We treated
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colocalized ﬁndings (PP≥ 80%) as “colocalized,” and other
ﬁndings that did not pass colocalization as “not colocalized.”
Mendelian randomization
Sclerostin versus bone phenotypes
We undertook two‐sample MR(26) to evaluate evidence of a
causal relationship between sclerostin measured in plasma and
bone phenotypes. We looked up GWAS results in distinct
cohorts to those used for the sclerostin GWAS, namely GEFOS
in the case of femoral neck and lumbar spine bone mineral
density (BMD; n= 32,961)(27) and UK Biobank in the case of
estimated BMD (eBMD; n= 426,824)(28) and (self‐reported)
fracture risk (n= 426,795).(29) In this initial analysis, sclerostin
was treated as the exposure and bone traits as the outcomes,
using sclerostin‐associated SNPs as the instrumental variables.
The multiple testing p value threshold was calculated as
p= 0.05 divided by the derived number of independent tests.
We used the random‐eﬀect inverse variance‐weighted (IVW)(30)
and Wald ratio(31) methods to obtain MR eﬀect estimates.
Heterogeneity analysis of the instruments were conducted
using Cochran Q test. Results were plotted as forest plots using
code derived from the ggplot2 package in R.(32) All MR analyses
were conducted using the MR‐Base TwoSampleMR R package
(github.com/MRCIEU/TwoSampleMR).(33) To identify potential
pleiotropic pathways, we conducted a phenomewide associa-
tion study (PheWAS) of the two top hits, rs215226 and
rs7241221, using the MR‐Base PheWAS tool (http://phewas.
mrbase.org/),(33) applying a Bonferroni p value threshold of
3 × 10−6, to account for multiple testing (number of
tests= 22,027).
Bidirectional MR
To investigate the possibility that BMD causally aﬀects levels of
serum sclerostin, we used summary results data from 49
conditionally independent autosomal variants reported in a
BMD GWAS using 32,744 GEFOS individuals.(27) We looked up
these variants in summary‐results GWAS data on sclerostin
from our meta‐analysis and found 39 instruments (including
two proxy SNPs) for femoral neck BMD and 38 instruments
(including two proxy SNPs) for lumbar spine BMD. When
applying bidirectional MR, we assume that SNPs used to proxy
BMD exert their primary association on BMD and that any
correlation with sclerostin levels is a consequence of a causal
eﬀect of BMD on sclerostin. We therefore applied Steiger
ﬁltering(34) and included 33 femoral neck BMD SNPs and 35
lumbar spine BMD SNPs, which exert their primary eﬀect on
BMD. See Supplemental Materials and Methods for additional
details.
Functional annotation
Predicted regulatory elements of the top association signals
For each locus associated with sclerostin, we identiﬁed all SNPs
with high LD from the top signal (LD r2 > 0.8) and identify their
DNA features and regulatory elements in noncoding regions of
the human genome using Regulomedb v1.1 (http://www.
regulomedb.org/).(35)
ATAC‐seq lookup in the top association regions
The Assay for Transposase Accessible Chromatin with high‐
throughput sequencing (ATAC‐seq) is a method for mapping
chromatin accessibility genomewide.(36) We intersected the
sclerostin‐associated SNPs (or proxy SNPs with LD r2 > 0.8) with
ATAC‐seq data generated from the proximal and distal femur of
an E15.5 mouse(36,37) lifted over to the orthologous positions in
human genome build hg19.
Gene expression quantitative trait loci (eQTLs) lookups for
sclerostin signals
We investigated whether the SNPs inﬂuencing serum sclerostin
level were driven by cis‐acting eﬀects on transcription by
evaluating the overlap between the sclerostin‐associated SNPs
and eQTLs within 500 kb of the gene identiﬁed, using data
derived from all tissue types from the GTEx consortium v7.(38)
Evidence of eQTL association was deﬁned as p< 1× 10−4 and
evidence of overlap of signal was deﬁned as high LD (r2≥ 0.8)
between eQTL and sclerostin‐associated SNPs in the region.
Where eQTLs overlapped with sclerostin‐associated SNPs, we
used the colocalization analysis to estimate the PP of each
genomic locus containing a single variant aﬀecting both serum
sclerostin level and gene expression level in diﬀerent tissues.
Equivalent analyses were performed in human primary
osteoblast cells(39) and cells derived from iliac crest bone
from 78 postmenopausal women(40) (see Supplemental Mate-
rials and Methods for further details).
Methylation quantitative trait loci (mQTLs) lookups
for sclerostin signals
We also investigated whether the SNPs inﬂuencing serum
sclerostin level were mediated by cis‐acting eﬀects on DNA
methylation by evaluating the overlap between the sclerostin‐
associated SNPs and mQTLs within 500 kb of the gene identiﬁed,
using data measured in blood cells. We queried data from
mQTLdb, which contained mQTL information at ﬁve diﬀerent
time points: ALSPAC children at birth, childhood, and adoles-
cence and ALSPAC mothers during pregnancy and at middle
age. These data are from the ARIES resource.(41) Evidence of
mQTL association was deﬁned as p< 1× 10−4 and evidence of
overlap of signal was deﬁned as high LD (r2≥ 0.8) between
mQTL and sclerostin‐associated SNPs in the region.
Results
Genomewide‐association study meta‐analysis
of serum sclerostin
GWAS results were available in 10,584 participants across four
cohorts (Table 1). Supplemental Figs. S1 and S2 show the
Manhattan plot and QQ plot of association results from the
ﬁxed‐eﬀect meta‐analysis of sclerostin in Europeans, respec-
tively (see Supplemental Fig. S3 for the QQ plots for each
study). There was little evidence of inﬂation of the association
results as the genomic inﬂation factor λ was 1.051 and the LD
score regression intercept 1.015.(23) Therefore, genomic control
correction was not applied to any of the meta‐analysis results.
LD score regression revealed that all common variants we
included in the meta‐analysis explained 16.3% of the pheno-
typic variance of sclerostin (H2= 0.163, SE= 0.052, p= 0.0017).
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Two loci were identiﬁed as being associated with serum
sclerostin at genomewide signiﬁcance level. Sixty‐nine SNPs in
the B4GLANT3 gene region were associated with sclerostin level
(Fig. 1A). The top hit rs215226 at this locus (β= 0.205 SD
change in serum sclerostin per A allele, SE= 0.014,
p= 4.60× 10−49, variance explained= 1.99%) was previously
reported to be associated with BMD estimated by heel
ultrasound (eBMD).(28) The second locus was in the GALNT1
gene region (Fig. 1B) with the top hit rs7241221 (β= 0.109 SD
per G allele, SE= 0.017, p= 4.40 × 10−11, variance explained=
0.39%). In addition, one SNP near the TNFRSF11B region
encoding OPG, rs1485303, showed a suggestive association
with sclerostin (β= 0.074 SD per G allele, SE= 0.014,
p= 7.70× 10−8, variance explained= 0.26%) (Fig. 1C). The
latter SNP is in moderate LD with a previously reported BMD‐
associated SNP rs1353171 (r2= 0.277 in the 1000 Genome
Europeans; distance between the two SNPs= 103,258 base
pairs).(42) The association signals of the GWAS meta‐analysis can
be found in Table 2 and Supplemental Table S1. Results of the
random‐eﬀects meta‐analysis were identical to those of the
ﬁxed‐eﬀects meta‐analysis (results not shown). The degree of
heterogeneity was low across studies for the GALNT1 signal
(I2= 0) and TNFRSF11B signal (I2= 0.53) but relatively high for
B4GALNT3 signal (I2= 0.78) (Supplemental Table S2). The latter
appeared to reﬂect a relatively strong association in 4D,
suggesting a possible interaction with the presence of CKD.
Conditional analyses on the lead SNP in each association locus
yielded no additional independent signals reaching genome-
wide signiﬁcance. The association of the two sclerostin SNPs
with femoral neck, lumbar spine, and heel BMD are presented
in Supplemental Table S3.
Only minor genetic inﬂuences on serum sclerostin were
observed within the SOST gene (chromosome 17, 41731099 to
41936156), which produces sclerostin. In total, four SOST SNPs
have previously been reported in association with BMD(28,43)
and one with fracture.(11) However, proxy SNPs for these SNPs
showed little or no association with serum sclerostin (Supple-
mental Table S4). We used the GWAS results to estimate the
genetic correlation between sclerostin and 11 bone pheno-
types using LD score regression via LD Hub.(24) We observed no
strong evidence of genetic correlation between sclerostin SNPs
and the bone phenotypes we tested (Supplemental Table S5).
Mendelian randomization and colocalization analysis of
sclerostin and bone phenotypes
Using two‐sample MR, we applied our GWAS results to larger
data sets to examine putative causal relationship between
sclerostin and bone phenotypes. The two SNPs robustly
associated with sclerostin (rs215226 in B4GALNT3 region and
rs7241221 in GALNT1 region) were used as genetic instruments
of the exposure. Dual‐energy X‐ray absorptiometry (DXA)‐
derived BMD and eBMD results from 32,961 GEFOS indivi-
duals(27) and 426,824 UK Biobank individuals,(28) respectively,
and self‐reported fracture of 426,795 individuals from UK
Biobank were used as outcomes. Contrasting with the genetic
correlation results, based on inverse variance‐weighted (IVW)
analysis, we observed that a higher level of serum sclerostin
was causally related to lower femoral neck BMD (β= –0.123 SD
change in BMD per SD increase in sclerostin, 95% conﬁdence
interval [CI] –0.195 to –0.051, p= 0.00074), lower eBMD
(β= –0.122 SD change in BMD per SD increase in sclerostin,
95% CI –0.140 to –0.104, p= 1.29 × 10−38) and higher fracture
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Fig. 1. Regional association plots and ENCODE annotation of the loci that reached or marginally reached genomewide signiﬁcance (p< 5 × 10−8) in
the meta‐analysis. The x axis indicates the physical position of each SNP on the chromosome speciﬁed, whereas the y axis denotes the evidence of
association shown as −log(p value). (A) The B4GLANT3 region; (B) the GALNT1 region; and (C) the TNFRSF11B region.
Table 2. Meta‐analysis Results for Loci That Reached or Marginally Reached Genomewide Signiﬁcance (p< 5 × 10−8)
Locus SNP EA OA EAF Gene Beta SE p Value Q Q_P I2
CHR12:591300 rs215226 A G 0.597 B4GALNT3 0.205 0.014 4.60 × 10−49 13.43 0.0038 0.777
CHR18:33152792 rs7241221 G A 0.772 GALNT1 0.109 0.017 4.40 × 10−11 0.955 0.812 0
CHR8:119976256 rs1485303 G A 0.568 TNFRSF11B 0.074 0.014 7.70 × 10−08 6.416 0.093 0.532
Locus= chromosome and position of the single‐nucleotide polymorphism [SNP]; EA= eﬀect allele; OA= other allele; EAF= eﬀect allele frequency;
gene= nearest gene to the sclerostin‐associated SNP; beta= SD change in serum sclerostin per eﬀect allele; SE= standard error; heterogeneity test:
Q= Cochrane’s Q statistics; Q_P= Cochrane’s Q p value; I2= I2 statistics.
risk (β= 1.117 odds ratio [OR] of fracture per SD increase in
sclerostin, 95% CI 1.009 to 1.237, p= 0.034) (Fig. 2). Point
estimates for the association between sclerostin level and
lumbar spine BMD were similar to those observed for femoral
neck and eBMD; however, 95% CIs were wide and crossed zero.
MR analyses based on single SNPs suggested that both SNPs
contributed to the overall causal eﬀects we observed (Supple-
mental Table S6). Heterogeneity analysis of the instruments
suggested that causal estimates were consistent across both
SNPs (p values of Cochran Q test > 0.05), with the exception of
estimates for lumbar spine BMD and fracture risk, likely
reﬂecting the lower power in these instances.(44) Genetic
signals for sclerostin and eBMD colocalized at both the
B4GALNT3 locus (PP= 99.7%) and GALNT1 locus (PP= 99.8%)
(Supplemental Table S7), further strengthening the evidence
of the putative causal relationship between sclerostin
and eBMD.
Because our genetic instrument for sclerostin was only based
on two SNPs, we were unable to apply methods such as Egger
regression to test the assumption that this instrument aﬀects
BMD via sclerostin as opposed to a separate causal pathway (ie,
horizontal pleiotropy). Therefore, to evaluate the possible role of
pleiotropy, we performed a phenomewide association study of
sclerostin‐associated signals. Rs215226 and rs1485303 were
associated with other heel ultrasound parameters closely related
to eBMD; rs215226 was also associated with height and body
mass, based on Bonferroni p value threshold of 3× 10−6
(Supplemental Tables S8 and S9). The strength of the association
between rs215226 and height, which approached that for eBMD,
raised the possibility of pleiotropy. However, in subsequent
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Fig. 2. Forest plot of putative causal relationship between serum sclerostin and bone phenotypes using Mendelian randomization. The x axis
represents the causal estimates and 95% conﬁdence intervals of SD change in BMD/eBMD and OR for fracture, per SD increase in sclerostin, as
calculated by inverse variance‐weighted method. The y axis lists the four bone phenotypes used in the MR analysis.
analyses, the relation between observed height and eBMD in UK
Biobank was found to be very weak, as reﬂected by Pearson
correlation (r)<0.1 (Supplemental Table S10). Moreover, associa-
tions between the three top hits and sclerostin were unchanged
after additional adjustment for height, as assessed in ALSPAC
(Supplemental Table S11). Taken together, these ﬁndings
suggest that a separate pathway via height is unlikely to
contribute to the relationship we observed between our genetic
instrument for sclerostin and BMD.
We also undertook bidirectional MR(45) to evaluate the
possibility of reverse causality between femoral neck BMD (or
lumbar spine BMD) and serum sclerostin level, based on SNPs
identiﬁed in GEFOS.(27) We modeled femoral neck BMD and
lumbar spine BMD as our exposure and serum sclerostin level
as our outcome. Having used Steiger ﬁltering to identify SNPs
predominantly related to BMD as opposed to sclerostin,(34) 33
of the 39 femoral neck BMD SNPs and 35 of the 38 lumbar
spine BMD SNPs were found to exert their primary eﬀect on
BMD (Supplemental Table S12). IVW results using 33 femoral
neck BMD SNPs suggested a positive relationship between
femoral neck BMD and sclerostin (β= 0.167 SD change in
sclerostin per SD change in BMD, 95% CI 0.050 to 0.285,
p= 0.005), whereas IVW results using 35 lumbar spine BMD
SNPs suggested a positive relationship between lumbar spine
BMD and sclerostin (β= 0.195 SD change in sclerostin per SD
change in BMD, 95% CI 0.080 to 0.310, p= 0.0009).
Sensitivity analyses were performed to evaluate horizontal
pleiotropy. MR Egger and weighted median methods showed
similar causal eﬀects (Supplemental Table S13 and Supplemental
Fig. S4A–D). There was no strong evidence of horizontal pleiotropy
for femoral neck BMD (Egger regression intercept= –0.0086,
p= 0.369) or lumbar spine BMD (Egger regression intercept=
–0.0104, p= 0.370). The heterogeneity test suggested some
heterogeneity across instruments for femoral neck (Cochrane
Q= 36.284, p= 0.0285) and lumbar spine BMD (Cochrane
Q= 54.721, p= 0.0136). To address the heterogeneity across
instruments, we further detected three outlier SNPs for femoral
neck BMD and lumbar spine BMD separately using Cochrane test
implemented in RadialMR R package.(46,47) The radial plot can be
found in Supplemental Fig. S5. As a sensitivity analysis, we removed
the outlier SNPs, and IVW results using the remaining 30 femoral
neck BMD and 32 lumbar spine BMD SNPs still suggested a positive
relationship between femoral neck BMD and sclerostin (β= 0.149,
95% CI 0.045 to 0.253, p= 0.005) as well as lumbar spine BMD and
sclerostin (β= 0.229, 95% CI 0.126 to 0.332, p= 1.4× 10−5)
(Supplemental Table S13).
Functional follow‐up
Predicted regulatory elements of the top association signals
We used Regulomedb to identify SNPs in high LD with the top
association signals (r2 > 0.8), which are likely to be located
within DNA regulatory elements.(35) Among the 24 tested SNPs,
we found three proxy SNPs showing high Regulomedb score
(Supplemental Table S14): rs1872426 (r2= 0.87 with the leading
SNP rs1485303 in the TNFRSF11B region) had a score of 1 f
(likely to comprise a DNA regulatory element and linked to
expression of a gene target), and rs215224 and rs4980826
(r2= 1 and 0.85 with the leading SNP rs215226, respectively, in
the B4GALNT3 region) had a score of 2b (likely to comprise a
DNA regulatory element) (see Supplemental Fig. S6 for
rs215224). We also examined whether variants we identiﬁed
are located at sites of accessible chromatin, indicative of DNA
transcriptional activator binding, by interrogating ATAC‐seq
data(36,37) generated from the proximal and distal femur.(48) In
the TNFRSF11B locus, one SNP, rs2073618, overlapped with an
ATAC‐seq peak, whereas in the B4GALNT3 locus, four SNPs
(rs12318530, rs215223, rs215224, and rs215225) fell in the same
ATAC‐Seq and Chip‐Seq peak (Supplemental Fig. S7 and
Supplemental Table S15).
Expression QTLs lookups for sclerostin signals
To evaluate if the sclerostin association signals inﬂuence
transcription of neighboring genes, we cross‐referenced the
sclerostin SNPs with cis‐expression data in tissues measured
in the GTEx consortium v7,(38) primary osteoblast cell
lines,(39) and iliac crest bone biopsies.(40) The top association
signal within the B4GALNT3 region, rs215226, showed a
strong positive association with B4GALNT3 gene expression
in arterial and ovarian tissue (Supplemental Table S16).
In contrast, a weaker inverse association with B4GALNT3
expression was observed in nervous tissue. Colocalization
analysis yielded strong evidence that sclerostin levels share
the same causal variant at this locus with arterial and ovarian
B4GLANT3 expression (probability >99%), whereas there was
no evidence of colocalization in the case of nervous tissue
(Supplemental Table S17). The association signal in the
GALNT1 region was positively associated with GALNT1
expression in adipose tissue and that of the neighboring
gene, INO80C, in adipose and heart tissue. In contrast,
sclerostin association signals in B4GALNT3, TNFRSF11B, and
GALNT1 were not associated with cis‐regulation of mRNA
expression in osteoblast cells (Supplemental Table S18) or
iliac crest bone biopsies (Supplemental Table S19). In trans‐
eQTL analyses, the GALNT1 signal was related to lower SOST
mRNA levels in iliac crest bone biopsies, particularly in
Aﬀymetrix chip analyses, whereas no association was
observed for B4GALNT3 or TNFRSF11B (Supplemental
Table S20).
Methylation QTLs lookups for sclerostin signals
To evaluate if our top association signals have the potential to
inﬂuence DNA methylation, we cross‐referenced the sclerostin
SNPs with methylation data as measured at adjacent CpG sites
in blood cells obtained at ﬁve diﬀerent time points (ALSPAC
children at birth, childhood, and adolescence; ALSPAC mothers
during pregnancy and at middle age).(41) We found that our top
hit rs215226, within B4GALNT3, was consistently associated
with extent of methylation at cg20907806 and cg26388816
across four time points (Supplemental Table S21). These
two CpG sites are located in a CpG island that overlapped
with one of the four ATAC‐seq peaks within the B4GALNT3
region (Supplemental Fig. S7, upper plot). The other potential
signal near TNFRSF11B, rs1485303, was associated with
methylation level at cg13268132 and cg17171407 at all ﬁve
time points.
B4galnt3 mRNA expression pattern (Supplemental Materials and
Methods)
In murine gene expression studies, B4galnt3mRNA was expressed
at highest levels in kidney, with relatively high levels of expression
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also observed in bone, particularly cortical bone (Fig. 3A). B4galnt3
mRNA was subsequently found to be expressed at relatively high
levels in osteoblast cultures derived from neonatal mouse
calvariae. The expression in osteoblast cultures was similar after
2 and 4 days of culture in osteogenic media (Fig. 3B). After 7 days
culture, there was a suggestive increase in B4galnt3 expression.
No expression was detected in in vitro cultured mouse bone
marrow macrophages or osteoclasts (Fig. 3B).
Discussion
In this two‐sample MR study, we ﬁrst performed a GWAS meta‐
analysis of serum sclerostin, identifying two genomewide
signiﬁcant loci (B4GALNT3 and GALNT1) and a further locus
close to genomewide signiﬁcance (TNFRSF11B). Together,
common genetic variants explained 16% of the variance of
serum sclerostin. By using rs215226 in B4GALNT3 and
rs7241221 in GALNT1 as instrumental variables, we subse-
quently examined causal relationships between serum
sclerostin and BMD, ﬁnding evidence of an inverse relationship
between sclerostin and BMD and a positive relationship with
fracture risk. Randomized control trial ﬁndings demonstrate
that systemic administration of the sclerostin inhibitor romo-
sozumab increases BMD and reduces fracture risk.(2,3) Our
present ﬁndings suggest that a similar beneﬁt may be obtained
by strategies aiming to reduce levels of circulating sclerostin.
However, whereas complete abrogation of sclerostin function
throughout the organism after romosozumab administration
appears to cause oﬀ‐target eﬀects such as cardiovascular
toxicity, pharmacological reduction of circulating sclerostin
levels could conceivably have a distinct safety proﬁle.
As well as providing evidence for a causal eﬀect of circulating
sclerostin on BMD and fracture risk, our GWAS ﬁndings raise the
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Fig. 3. B4galnt3 expression in mice and in in vitro cultured osteoblasts and osteoclasts. (A) B4galnt3 mRNA tissue expression in adult female mice,
presented as percentage of cortical bone± SEM (n= 6). (B) B4galnt3 mRNA expression in mouse calvarial osteoblasts cultured in osteogenic media for
2, 4, and 7 days (D). Mouse bone marrow macrophages cultured with macrophage colony‐stimulating factor (M) or M‐CSF+ RANKL (M/RL) to induce
osteoclast diﬀerentiation. Percentage of expression D2± SEM. N.D.= not detectable.
intriguing possibility that circulating sclerostin levels are
inﬂuenced by the activity of glycosylation enzymes, suggesting
a means by which these levels might be targeted pharmaco-
logically. B4GALNT3 is an N‐acetyl‐galactosaminyltransferase
enzyme that adds a terminal LacdiNAc disaccharide to target
glycocoproteins, whereas GALNT1 is an enzyme‐causing
mucin‐type O‐linked glycosylation. Association signals with
sclerostin at these two loci colocalized with those for eBMD,
consistent with the possibility that genetic variation in
B4GALNT3 and GALNT1 alters BMD via changes in serum
sclerostin.
B4GALNT3 has previously been reported to be expressed in
multiple human tissues, including arterial, gastrointestinal tract,
and testis.(49) In the present study, in mice, B4GALNT3 mRNA was
expressed at highest levels in kidney and cortical bone. This
ﬁnding is consistent with high levels of B4GALNT3 mRNA
expression in renal tissue from human fetal samples in the NIH
Roadmap Epigenomics Mapping Consortium (http://www.
roadmapepigenomics.org/data/). The B4GALNT3 locus we identi-
ﬁed showed strong cis‐regulatory activity in eQTL studies in arterial
tissue, which was conﬁrmed by the colocalization analysis. The
eﬀect allele associated with higher sclerostin levels was associated
with considerably greater B4GALNT3 mRNA levels in arterial tissue,
suggesting that B4GALNT3 acts to increase sclerostin levels.
Sclerostin is a glycoprotein, which, like B4GALNT3, is also
expressed at a number of sites outside the skeleton, including
arterial tissue.(50) Whereas sclerostin protein is detected in
multiple tissues, extraskeletal sclerostin mRNA is mainly
expressed in the kidney, reﬂecting renal tubular expression
(www.proteinatlas.org), suggesting this may be the predomi-
nant extraskeletal source of circulating sclerostin. It’s tempting
to speculate that sclerostin acts as a substrate for B4GALNT3,
such that formation of a terminal LacdiNAc moiety protects
sclerostin from degradation and clearance from the circulation
(Fig. 4). This interpretation is analogous to the role of GALNT3, a
Golgi enzyme that acts to O‐glycosylate another osteocyte‐
derived protein, FGF23, protecting it from degradation.(51)
Given our ﬁnding that B4GALNT3 is expressed at high levels in
the kidney, a major source of extraskeletal sclerostin, the
kidney may represent the principal source of glycosylated
sclerostin. To the extent that activity of renal sclerostin
glycosylation inﬂuences BMD via changes in circulating
sclerostin levels, rather than the latter simply reﬂecting
“spillover” from sclerostin within the bone microenvironment,
a two‐way exchange may exist whereby perturbations in
circulating sclerostin levels alter concentrations within bone.
The GALNT1 locus, which was also associated with serum
sclerostin, expresses an enzyme in humans that initiates
O‐glycosylation(52) and may act similarly to alter sclerostin
levels by reducing sclerostin clearance.
In addition, we found that B4GALNT3 is expressed at relatively
high levels in bone, particularly cortical bone, where sclerostin is
also preferentially expressed, reﬂecting its production by osteo-
cytes. Speciﬁcally, B4GALNT3 mRNA expression was detected in
osteoblast cultures derived from mouse calvariae but not in bone
marrow macrophage cultures induced to form osteoclasts. Further
studies are required to establish whether B4GALNT3 is expressed in
osteocytes as well as osteoblasts. However, to the extent that
B4GALNT3 and sclerostin expression overlap within bone, theore-
tically, B4GALNT3‐dependent glycosylation might inﬂuence local
sclerostin activity in a variety of ways, including altered production.
Although genetic variation in B4GALNT3 might conceivably
inﬂuence circulating sclerostin via a primary action in bone, against
this suggestion, there was little evidence of B4GALNT3 cis‐regulatory
activity in osteoblasts and bone tissue. Furthermore, the B4GALNT3
SNP did not appear to act as a trans‐eQTL signal for SOST in bone.
However, eQTL studies in bone had considerably less power than
those in other tissues analyzed (285 and 78 individuals for tibial
artery and bone biopsy studies, respectively).
Although our analyses were primarily intended to identify loci
associated with serum sclerostin, there is some evidence to suggest
that rs215224 was responsible for the underlying genetic signal at
the B4GALNT3 locus. This SNP is in perfect LD with our top
B4GALNT3 hit, rs215226. Rs215224 shows strong evidence of
alteration of transcriptional activity from RegulomeDB, supported
by the ﬁnding that this SNP falls within a site of open chromatin, as
assessed by ATAC‐seq in E15.5 mouse femurs. That said, although
rs215224 was also associated with diﬀerential methylation at two
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Fig. 4. Proposed exchange of sclerostin between skeletal and systemic compartments. Sclerostin, synthesized by osteocytes, is present within the
bone microenvironment but also exchanges with the systemic circulation, where it is produced by several extraskeletal tissues, including the kidney.
Whereas locally produced sclerostin is largely responsible for actions of sclerostin on bone, factors that inﬂuence circulating levels may also play a
role, including variation in activity of B4GALNT3, which we propose protects sclerostin from degradation through generation of a terminal LacdiNAc.
distinct CPG sites within B4GALNT3, one of which coincided with an
ATAC‐seq site, these were at distinct locations within the gene.
Genetic variation within the SOST gene appeared to have
relatively weak associations with serum sclerostin, including SOST
SNPs previously reported to be associated with BMD or hip fracture.
This suggests that previously identiﬁed SOST SNPs inﬂuence BMD
and hip fracture by altering local sclerostin activity in bone,
independently of circulating sclerostin levels. That said, further
studies with a larger sample size are needed to establish the
contribution of genetic variation within the SOST locus to serum
sclerostin. In terms of other genetic inﬂuences on serum sclerostin,
the association between TNFRSF11B and serum sclerostin was just
below our threshold. TNFRSF11B is a well‐established BMD locus,(42)
and the protein product, OPG, plays a major role in regulating bone
resorption.(53) However, against the suggestion that altered OPG
production mediates this genetic association, eQTL studies in heart
tissue revealed that rs1485303 (the most strongly associated SNP at
this locus) is strongly associated with expression of the adjacent
gene, COLEC10.
Whereas MR analyses using B4GLANT3 and GALNT1 as genetic
instruments supported a causal inﬂuence of higher sclerostin
levels in reducing BMD, bidirectional MR analysis suggested that
if anything, higher BMD leads to greater sclerostin levels. This
apparent positive inﬂuence of BMD on sclerostin levels is in line
with previous reports of elevated sclerostin levels in individuals
with extreme elevations in BMD(54) and of positive associations
between serum sclerostin levels and lumbar spine and femoral
neck BMD in postmenopausal women.(40) One explanation for
this latter relationship is that individuals with higher BMD have a
relatively large amount of bone tissue, and therefore, produce
more sclerostin as result of having greater numbers of
osteocytes. Additionally, these causal relationships may repre-
sent components of a regulatory feedback pathway, such that
greater bone formation leading to increased BMD stimulates
sclerostin production, which then feed backs to reduce bone
formation and hence limit BMD gains.
Strengths and weaknesses
This study represents the ﬁrst MR study of sclerostin, based on the
only serum sclerostin GWAS reported to date. Of the loci identiﬁed,
B4GALNT3 had a relatively strong association for a common variant
(ie, 0.2 SD change in serum sclerostin per allele). Although we
performed a GWAS meta‐analysis to maximize statistical power, the
association between the B4GALNT3 locus and sclerostin also
reached genomewide signiﬁcance in three of the four participating
cohorts. That said, the total GWAS study sample of around 11,000
was relatively small, and further replication of our ﬁndings would
be desirable. Only two loci passed evidence thresholds for
application in our MR analysis, and so it was not possible to apply
methods such as Egger regression for evaluating horizontal
pleiotropy, to analyze the causal pathway between sclerostin and
BMD. Nevertheless, colocalization analysis strongly suggested that
both loci comprising the sclerostin instrument inﬂuence BMD via
changes in circulating sclerostin, as opposed to a separate, BMD‐
speciﬁc pathway. Although the genetic association signal between
B4GALNT3 and sclerostin showed high heterogeneity, this appeared
to reﬂect a relatively strong signal in the 4D cohort, comprising
individuals with end‐stage kidney disease, and is unlikely to limit
application as a genetic instrument in the general population. In
terms of other limitations, diﬀerent methods were used to measure
sclerostin in the participating cohorts; as well as diﬀerent ELISAs,
the MANOLIS cohort used the OLINK proteomics platform.
Nonetheless, similar genetic associations were observed across all
four cohorts, suggesting diﬀerent sclerostin measurement methods
are unlikely to have importantly impacted on our results.
Conclusions
Having applied ﬁndings from a GWAS meta‐analysis for serum
sclerostin in a two‐sample MR framework, we established a
causal relationship between higher circulating sclerostin levels,
reduced BMD, and increased fracture risk. Hence, strategies for
reducing circulating sclerostin may prove valuable in treating
osteoporosis. Conceivably, these might include targeting of
glycosylation enzymes, encoded by the two genomewide
signiﬁcant loci for sclerostin we identiﬁed.
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